Positive Results From Phase IIa Study Pave Way For Phase IIb Trial Of DG051 For The Prevention Of Heart Attack

deCODE genetics (Nasdaq: DCGN) announced positive topline results from its Phase IIa clinical trial for DG051, the company’s leukotriene A4 hydrolase inhibitor being developed for the prevention of heart attack. With these results, the company has finalized the design of a Phase IIb trial for which it expects to begin enrolling patients this spring.

More: continued here

Filed under: Clinical Trials on January 12th, 2008